Abstract
In recent years, steady progress has been made in synthesizing and characterizing engineered nanoparticles, resulting in several approved drugs and multiple promising candidates in clinical trials. Regulatory agencies such as the Food and Drug Administration and the European Medicines Agency released important guidance documents facilitating nanoparticle-based drug product development, particularly in the context of liposomes and lipid-based carriers. Even with the progress achieved, it is clear that many barriers must still be overcome to accelerate translation into the clinic. At the recent conference workshop “Mechanisms and Barriers in Nanomedicine” in May 2023 in Colorado, U.S.A., leading experts discussed the formulation, physiological, immunological, regulatory, clinical, and educational barriers. This position paper invites open, unrestricted, nonproprietary discussion among senior faculty, young investigators, and students to trigger ideas and concepts to move the field forward.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 13983-13999 |
| Number of pages | 17 |
| Journal | ACS nano |
| Volume | 18 |
| Issue number | 22 |
| DOIs | |
| State | Published - Jun 4 2024 |
Funding
This conference was primarily funded by the R13EB034603 grant (to D.S. and T.J.A) from the National Institute of Biomedical Imaging and Bioengineering and the National Cancer Institute of the National Institutes of Health, USA. D.S., T.J.A., and N.J.S. would like to acknowledge the help of the following sponsors: the Associate Dean for Research, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of Colorado; the Colorado Center for Nanomedicine and Nanosafety; the University of Colorado Cancer Center P30 grant (P30CA046934); the Colorado Clinical Translational Science Institute (UM1TR004399); Moderna Inc; and PerkinElmer, Inc. D.S. and I.V.B. acknowledge the National Institutes of Health grant R01CA257958. W.C.W.C. acknowledges the Canadian Institute of Health Research, the Natural Sciences and Engineering Research Council of Canada, the National Centre of Excellence \u2013 NMIN Network, and the Canadian Research Chair\u2019s Program. T.T. was funded by the Estonian Research Council (grants PRG230, PRG1788) and EuronanomedII projects ECM-CART and iNanoGun. S.K.L. acknowledges the support of the National Institutes of Health R01HL141934 and 3UM1AI109565-08S1. R.S. acknowledges the support of the National Institutes of Health R01CA207222. S.M.M. acknowledges support by the European Union\u2019s Horizon 2020 programme funded under H2020-EU.1.3. \u2013 Excellent Science \u2013 Marie Sk\u0142odowska-Curie Actions, grant agreement ID - 956544 (DIRNANO: Directing the Immune Response through Designed Nanomaterials). Y.B. lab was supported by the Barenholz Fund. This fund was established with a portion of Barenholz royalties, which the Hebrew University assigned to support research in the Barenholz lab, including this study. T.L. gratefully acknowledges support from the European Research Council (ERC: Meta-Targeting and PRIME), German Research Foundation (DFG: RTG2735, SFB1066), and German Federal Ministry of Research and Education (BMBFPP-TNBC). D.P. acknowledges the support from the European Research Council (ERC Adv. Grant # 101055029), The EXPERT project (European Union\u2019s Horizon 2020 research and innovation programme (under grant agreement # 825828) B.G. acknowledges support from Department of Defense/U.S. Army Medical Research grant W81XWH2110012 and National Institute for Neurological Disorders and Stroke (NINDS), R21 NS127265. J.N. acknowledges funds from the National Institutes of Health (R01HL174038 and R01HL161456).
Keywords
- barriers
- complement
- delivery
- formulation
- inflammation
- mRNA
- nanomedicine
- translation
- tumor
ASJC Scopus subject areas
- General Materials Science
- General Engineering
- General Physics and Astronomy